Secondary prevention after minor stroke and TIA - usual care and development of a support program

PLoS One. 2012;7(12):e49985. doi: 10.1371/journal.pone.0049985. Epub 2012 Dec 17.

Abstract

Background: Effective methods of secondary prevention after stroke or TIA are available but adherence to recommended evidence-based treatments is often poor. The study aimed to determine the quality of secondary prevention in usual care and to develop a stepwise modeled support program.

Methods: Two consecutive cohorts of patients with acute minor stroke or TIA undergoing usual outpatient care versus a secondary prevention program were compared. Risk factor control and medication adherence were assessed in 6-month follow-ups (6M-FU). Usual care consisted of detailed information concerning vascular risk factor targets given at discharge and regular outpatient care by primary care physicians. The stepwise modeled support program additionally employed up to four outpatient appointments. A combination of educational and behavioral strategies was employed.

Results: 168 patients in the observational cohort who stated their openness to participate in a prevention program (mean age 64.7 y, admission blood pressure (BP): 155/84 mmHg) and 173 patients participating in the support program (mean age 67.6 y, BP: 161/84 mmHg) were assessed at 6 months. Proportions of patients with BP according to guidelines were 50% in usual-care and 77% in the support program (p<0.01). LDL<100 mg/dl was measured in 62 versus 71% (p = 0.12). Proportions of patients who stopped smoking were 50 versus 79% (p<0.01). 72 versus 89% of patients with atrial fibrillation were on oral anticoagulation (p = 0.09).

Conclusions: Risk factor control remains unsatisfactory in usual care. Targets of secondary prevention were met more often within the supported cohort. Effects on (cerebro-)vascular recurrence rates are going to be assessed in a multicenter randomized trial.

Trial registration: ClinicalTrials.gov NCT01586702.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Ambulatory Care / methods*
  • Female
  • Humans
  • Ischemic Attack, Transient / prevention & control*
  • Ischemic Attack, Transient / therapy*
  • Male
  • Quality of Health Care
  • Risk Factors
  • Secondary Prevention / methods*
  • Stroke / prevention & control*
  • Stroke / therapy*

Associated data

  • ClinicalTrials.gov/NCT01586702

Grants and funding

HJA received honoraria payment from Lundbeck Pharma, Boehringer Ingelheim Pharma, Takeda Pharma, Sanofi Synthelabo, Bayer Vital, UCB Pharma; Dr. C.H. Nolte from Boehringer Ingelheim Pharma, Takeda Pharma. PUH received research support from the European Union, the German Stroke Foundation, the Stanley Thomas Johnson Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.